An intravenous neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult and pediatric patients ≥ 12 years of age who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive.
An intravenous neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult and pediatric patients ≥ 12 years of age who are anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibody positive.